Navigation Links
XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
Date:10/10/2008

WASHINGTON and MENLO PARK, Calif., Oct. 10 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that it plans to present long-term follow-up data from the CUSTOM I, II and III clinical trials next week at the Cardiovascular Research Foundation's (CRF) twentieth annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC. The CUSTOM clinical trials are prospective studies designed to investigate the safety and efficacy of the Custom NX(R) drug eluting stent (DES) system in treating patients with coronary artery disease.

Pieter R. Stella, MD, Director, Cardiovascular Research, University Medical Centre Utrecht, The Netherlands, and one of the CUSTOM clinical trial investigators, will present the data during a scientific symposium entitled, "The Drug Eluting Stent Summit, Part II," on Monday, October 13, 2008 at 2:54 p.m., eastern time, at the Walter E. Washington Convention Center, Ballroom C, Level 3. The data presentation will be posted on the XTENT website at http://www.xtentinc.com.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Pri
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
2. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. XTENT Announces First Quarter 2008 Financial Results
5. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
6. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
7. Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
8. XTENT Announces European Regulatory Update
9. XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...tCall/ -- GeoVax Labs, Inc.,(OTC Bulletin Board: ...loping,human vaccines for diseases caused by HIV-...ious agents, announced today that the launch of it...n twelve sites across North and South America.,Th... National Institutes of,Health (NIH), and the HIV...
(Date:11/28/2008)...28 German biotech company,Partec ...HIV monitoring and,AIDS patient follow-up diagnos...e year 2008, 2.5 million patient tests have been p...ordable "CyFlow" system, supporting already,more ... introduction of the,Partec innovation, the avera...
(Date:11/26/2008)...utomation and intelligent clinical applications ta... level , , CHICAGO, Ill., Nov. 26 /PRNewswi...ens.com/healthcare ) highlights the ACUSON S2000(...e world,s first multi-use, automated volume breast...y and Annual Meeting of the Radiological Society o...
(Date:11/25/2008)...against expanding statin use broadly in wake of AH...ov. 25 JUPITER, a clinical trial s...r risk of healthy patients with elevated CRP, shou..., according to a national poll directed at health ...n the online poll conducted by medical news site M...
Breaking Medicine Technology:GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Nearly Half of Newly Diagnosed HIV AIDS Cases in Los Angeles County Are Among Latinos 27301 1Nearly Half of Newly Diagnosed HIV AIDS Cases in Los Angeles County Are Among Latinos 27301 2Vista Partners Updates Coverage on Arana Therapeutics 28ASX 3A AAH 3B AIM 3A AAHx 29 Raises Target Price to AU 241 65 8239 1Vista Partners Updates Coverage on Arana Therapeutics 28ASX 3A AAH 3B AIM 3A AAHx 29 Raises Target Price to AU 241 65 8239 2Excess Drinking Shrinks the Brain 27296 1Excess Drinking Shrinks the Brain 27296 23 Michigan Counties Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 27293 13 Michigan Counties Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 27293 2
...-Jun 7, 2007 - Clinical results from a,Phase II st...eadache Society (AHS) annual meeting showed that M...lated peptide (CGRP),receptor antagonist, signific...r dosing compared to placebo, and the relief was,s...ell tolerated in,the study. Responses specific to ...
...07, 2007 /PRNewswire-FirstCall/ --,Mymetics Corpor...ating that the Company,s HIV vaccine elicited neut...mate model. Mucosal IgA,antibodies are considered ...ion by HIV. The data were presented by Sylvain,Fle... an oral,presentation titled, "Without Mucosal Adj...
Other Medicine Technology:Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 2Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 3Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 4
(Date:12/1/2008)...lergy Friendly, Toy Puppies to the Obama Daughters...ire/ -- Much has been made of President-Elect Obam...rns about his daughter,s asthma and allergies, and...aking a decision. So, in the meantime, the Asthma...ing 2 "asthma & allergy friendly" toy puppies ...
(Date:12/1/2008)...und that the availability of a portable eight-slic... room can significantly increase the number of str...treatment. Results of the study, conducted at Nort...lem, Mass., will be presented today at the annual ...ca (RSNA). , "The hospital,s acquisition of a p...
(Date:12/1/2008)...s that computed tomography (CT) colonography, also...o screen for two diseases at oncecolorectal cancer...dults over age 50. Results of the study will be pr...gical Society of North America (RSNA). , "With C...ectal cancer, we were able to identify patients wi...
(Date:12/1/2008)... As the connection between second-hand smoke and c...islation was passed to reduce such passive smoking...shed in the January 2009 issue of the American Jo...e University of California, San Francisco, Partner...recalibrated the CHD Policy Model to better predic...
Breaking Medicine News(10 mins):Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:Portable CT increases chance of stroke survival and recovery 2Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2
...ommonwealth University Massey Cancer Center have d...ns, using small molecules containing platinum, whi...l be beneficial for the researchers to develop new...cer by selectively targeting proteins known as zin...
...-run hospitals across the country were restored to...nti-quota protests following a directive from the ...institutions like AIIMS, MAMC, Lady Hardinge and S...ioning with junior doctors reporting back to duty....
...ve found that an amphetamine-like stimulant has a ...hyperactivity disorder (ADHD) // . A new study un... a drug that is widely used to treat ADHD, appears...sn't as easily distracted by any stimuli from the ...
...ar-old adults in UK revealed that above half of th.../ To make themselves intoxicate, about 18 per cent...ol. About 59 per cent and 43 per cent of people in...24 and 25-34 respectively, and who drank to get dr...
Other Medicine News:Health News:New Research May Be Useful for Developing Drugs for HIV and Cancer 2Health News:Ritalin Could Help In Focussing The Mind 2
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile.
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex
Medicine Products: